<?xml version="1.0" encoding="UTF-8"?>
<article version="1.0" id="60d53b3e0e81524c9c2d2365">
  <languages>
    <lang>en_GB</lang>
    <lang>zh_CN</lang>
    <lang>zh_TW</lang>
  </languages>
  <pubdate>2021-06-28T14:54:06+00:00</pubdate>
  <ads_disabled>false</ads_disabled>
  <headline>
    <title lang="en_GB">The big-pharma firm that saw the future</title>
    <title lang="zh_CN">这家大药厂预见了未来</title>
    <title lang="zh_TW">這家大藥廠預見了未來</title>
    <fly_title lang="en_GB">Schumpeter</fly_title>
    <fly_title lang="zh_CN">熊彼特</fly_title>
    <fly_title lang="zh_TW">熊彼特</fly_title>
    <section lang="en_GB">Business</section>
    <section lang="zh_CN">商业</section>
    <section lang="zh_TW">商業</section>
  </headline>
  <body>
    <rubric lang="en_GB">Long ago Roche bet on personalised health care. Now its time has come</rubric>
    <rubric lang="zh_CN">罗氏在很久以前就押注个性化医疗。它的时机到了</rubric>
    <rubric lang="zh_TW">羅氏在很久以前就押注個性化醫療。它的時機到了</rubric>
    <content>
      <image>
        <url lang="en_GB">images/60d53b3e0e81524c9c2d2365_en_GB_0_quipimage.jpeg</url>
        <url lang="zh_CN">images/60d53b3e0e81524c9c2d2365_zh_CN_0_quipimage.jpeg</url>
        <url lang="zh_TW">images/60d53b3e0e81524c9c2d2365_zh_CN_0_quipimage.jpeg</url>
        <caption lang="en_GB"/>
        <caption lang="zh_CN">​</caption>
        <caption lang="zh_TW">​</caption>
      </image>
      <paragraph>
        <copy lang="en_GB">ROCHE IS A strange entity. The Swiss giant is the world’s second-biggest drugmaker and one of big pharma’s most profitable firms. But its largest shareholding group, mostly descended from Fritz Hoffmann-La Roche, who founded the company in 1896, is led by André Hoffmann, a nature lover and sustainability advocate who believes that the purpose of business is not mainly to make money. Even its bosses are discouraged from making a quick franc. Severin Schwan, an Austrian who has led the company since 2008, is only Roche’s seventh CEO in 125 years. Much of his pay is tied up in company stock for ten years, giving him, as he puts it, “literally a vested interest” in its long-term future.</copy>
        <copy lang="zh_CN">罗氏是个奇特的存在。这家瑞士巨头是全球第二大制药公司，也是最赚钱的大药厂之一。但它最大的持股群体（主要是于1896年创立公司的弗里茨·霍夫曼-罗氏[Fritz Hoffmann-La Roche]的后裔）的领头人安德烈·霍夫曼（André Hoffmann）热爱自然，倡导可持续发展，认为企业的主要目的不在赚钱。罗氏甚至也不鼓励它的老板们去赚快钱。从2008年开始领导公司的奥地利人塞维林·施万（Severin Schwan）仅仅是罗氏创立125年来的第七任首席执行官。十年来，他的大部分薪酬都与公司股票挂钩，用他自己的话说，这让他从公司的长远未来中获得“实实在在的既得利益”。</copy>
        <copy lang="zh_TW">羅氏是個奇特的存在。這家瑞士巨頭是全球第二大製藥公司，也是最賺錢的大藥廠之一。但它最大的持股群體（主要是於1896年創立公司的弗里茨·霍夫曼-羅氏[Fritz Hoffmann-La Roche]的後裔）的領頭人安德烈·霍夫曼（André Hoffmann）熱愛自然，倡導可持續發展，認為企業的主要目的不在賺錢。羅氏甚至也不鼓勵它的老闆們去賺快錢。從2008年開始領導公司的奧地利人塞維林·施萬（Severin Schwan）僅僅是羅氏創立125年來的第七任首席執行官。十年來，他的大部分薪酬都與公司股票掛鉤，用他自己的話說，這讓他從公司的長遠未來中獲得“實實在在的既得利益”。</copy>
      </paragraph>
      <paragraph>
        <copy lang="en_GB">Another thing sets Roche apart from the crowd. For two decades it has nurtured an unflashy diagnostics division alongside its mainstay of drug production, in an effort to create more personalised health care. This unit, which accounts for almost a quarter of sales, has generated lower margins than pharmaceuticals, and puts off the sort of investors who yearn only for blockbuster medicines. Had it not been for the Hoffmanns’ patience, some suspect, activists would have forced Roche to sell it or spin it off long ago.</copy>
        <copy lang="zh_CN">还有一件事让罗氏与众不同。除了制药这一支柱业务，它在过去20年里还培育了一个不起眼的诊断部门，致力于打造更个性化的医疗服务。这个部门贡献了总销售额的近四分之一，但利润低于制药，这让那些只盯着畅销药的投资者望而却步。有些人怀疑，如果不是霍夫曼够耐心，维权投资者早就逼迫罗氏出售或剥离这个部门了。</copy>
        <copy lang="zh_TW">還有一件事讓羅氏與眾不同。除了製藥這一支柱業務，它在過去20年里還培育了一個不起眼的診斷部門，致力於打造更個性化的醫療服務。這個部門貢獻了總銷售額的近四分之一，但利潤低於製藥，這讓那些只盯着暢銷葯的投資者望而卻步。有些人懷疑，如果不是霍夫曼夠耐心，維權投資者早就逼迫羅氏出售或剝離這個部門了。</copy>
      </paragraph>
      <paragraph>
        <copy lang="en_GB">And yet in the past year or so the ability to diagnose a disease in its early stages has fully come into its own. The division has helped the company through the covid-19 pandemic. Roche was not one of the star vaccine producers, but its workaday PCR and antigen tests bolstered profits despite a slowdown in cancer treatments, its biggest business. Moreover, advances in gene sequencing and other techniques from molecular biology helped identify SARS-CoV-2, the covid-19 virus, as well as ways to fight it. That has highlighted the value of combining biotechnology and diagnostics. These are both fields in which Roche excels.</copy>
        <copy lang="zh_CN">但在过去一年左右的时间里，诊断处于早期阶段的疾病的能力充分显现了其价值。这个部门帮助罗氏捱过了新冠疫情的冲击。生产疫苗的明星厂商中没有罗氏，但它的常规PCR和抗原检测仍然提高了公司利润，即便它规模最大的抗癌业务增长放缓。此外，基因测序和其他源自分子生物学的方法帮助识别了新冠病毒及寻找抗击手段。这凸显了生物技术和诊断学相结合的价值，而这两个领域都是罗氏的强项。</copy>
        <copy lang="zh_TW">但在過去一年左右的時間裡，診斷處於早期階段的疾病的能力充分顯現了其價值。這個部門幫助羅氏捱過了新冠疫情的衝擊。生產疫苗的明星廠商中沒有羅氏，但它的常規PCR和抗原檢測仍然提高了公司利潤，即便它規模最大的抗癌業務增長放緩。此外，基因測序和其他源自分子生物學的方法幫助識別了新冠病毒及尋找抗擊手段。這凸顯了生物技術和診斷學相結合的價值，而這兩個領域都是羅氏的強項。</copy>
      </paragraph>
      <paragraph>
        <copy lang="en_GB">Far from shedding diagnostics, Roche is now doubling down on it, expanding into digitisation and advanced data analytics to create individually tailored cancer treatments. This is, says Tim Haines, boss of Abingworth, a biotech venture-capital firm, “the golden age of diagnostics”. Bets placed years ago are making the stodgy-sounding, Basel-based company look prescient.</copy>
        <copy lang="zh_CN">罗氏非但没有放弃诊断业务，反而在加倍投入，将它扩展到数字化和先进的数据分析领域，以创建个性化的癌症治疗方案。生物技术风险投资公司Abingworth的老板蒂姆·海恩斯（Tim Haines）说，现在是“诊断技术的黄金时代”。多年前的押注让这家听起来古板守旧、总部位于巴塞尔的公司看起来颇有先见之明。</copy>
        <copy lang="zh_TW">羅氏非但沒有放棄診斷業務，反而在加倍投入，將它擴展到數字化和先進的數據分析領域，以創建個性化的癌症治療方案。生物技術風險投資公司Abingworth的老闆蒂姆·海恩斯（Tim Haines）說，現在是“診斷技術的黃金時代”。多年前的押注讓這家聽起來古板守舊、總部位於巴塞爾的公司看起來頗有先見之明。</copy>
      </paragraph>
      <paragraph>
        <copy lang="en_GB">Mr Schwan, whose background is in diagnostics, can barely contain his excitement. After a long conversation with The Economist, he came back for more a day later. As he explains, cancer is a panoply of diseases based on individual mutations. Diagnostics identifies genetic and other differences between patients, leading to the creation of more personalised treatments. The tailor-made market, by definition, is smaller than the one for blockbuster drugs, but if patients respond better to treatment, the value of drugs can be proportionally higher. Sifting through oceans of genomic data can produce yet more precision.</copy>
        <copy lang="zh_CN">本身是公司诊断部门元老的施万对此抑制不住地兴奋。在与本刊交流许久后，过了一天他又前来畅谈。他解释道，癌症是基于个体突变的一整组疾病。诊断学识别不同患者在基因和其他方面的差异，据此制定更个性化的治疗方案。个性化医疗的市场势必小于畅销药物，但如果患者对治疗的反应更好，药物的价值也会相应提高。筛查海量基因组数据还可以生成更精确的判断。</copy>
        <copy lang="zh_TW">本身是公司診斷部門元老的施萬對此抑制不住地興奮。在與本刊交流許久後，過了一天他又前來暢談。他解釋道，癌症是基於個體突變的一整組疾病。診斷學識別不同患者在基因和其他方面的差異，據此制定更個性化的治療方案。個性化醫療的市場勢必小於暢銷藥物，但如果患者對治療的反應更好，藥物的價值也會相應提高。篩查海量基因組數據還可以生成更精確的判斷。</copy>
      </paragraph>
      <paragraph>
        <copy lang="en_GB">Accumulating reams of information on patients has long sat awkwardly with concerns about medical privacy. Less so now, Mr Schwan believes. He says the pandemic has helped change the mood in two ways. First, the use of data-crunching to speed up the fight against covid-19 has made health authorities, hospitals and doctors more amenable to the idea of sharing medical records—provided the information is anonymised. This is, after all, biotech, not big tech. “We are not in the advertising business,” he says. Second, regulators have shown what he describes as an “incredible” willingness to speed up drug approval by gaining access to clinical-trial data in real time. “Why should we not do the same for life-saving cancer medicines?”</copy>
        <copy lang="zh_CN">长期以来，搜集大量患者信息这件事总卡在担忧医疗隐私的问题上。施万相信现在没那么难办了。他说疫情从两个方面改变了氛围。首先，运用数据处理加快抗击新冠疫情让卫生主管部门、医院和医生更加乐意共享病历了——前提是信息匿名。这毕竟是生物科技，不是大科技。“我们又不是在做广告生意。”他说。其次，监管机构表现出了他描述为“不可思议”的意愿，愿意通过实时获取临床试验数据来加快药物审批。“在治疗癌症的救命药上，我们难道不应该也这么做吗？”</copy>
        <copy lang="zh_TW">長期以來，搜集大量患者信息這件事總卡在擔憂醫療隱私的問題上。施萬相信現在沒那麼難辦了。他說疫情從兩個方面改變了氛圍。首先，運用數據處理加快抗擊新冠疫情讓衛生主管部門、醫院和醫生更加樂意共享病歷了——前提是信息匿名。這畢竟是生物科技，不是大科技。“我們又不是在做廣告生意。”他說。其次，監管機構表現出了他描述為“不可思議”的意願，願意通過實時獲取臨床試驗數據來加快藥物審批。“在治療癌症的救命葯上，我們難道不應該也這麼做嗎？”</copy>
      </paragraph>
      <paragraph>
        <copy lang="en_GB">Roche, which has recently fallen behind Merck, an oncology rival, in immunotherapy treatments, has been eagerly waiting for this digital tide to turn. Two American acquisitions in 2018 could prove particularly fruitful. One is Foundation Medicine, a gene-sequencing company that can identify cancers from DNA in blood samples, instead of from tumour biopsies. The other is Flatiron Health, a specialist in cancer-related health records that generates data on patients from the real world, supplementing clinical trials. Both produce what Roche calls insights on cancer. Like its diagnostics business, not only do they help it further its own drug development; they also sell services to rivals, making them businesses in their own right. They are not yet profitable, but one day, Mr Schwan says, the “insights” business could be a third pillar for Roche—as big, if not bigger, than diagnostics and pharma.</copy>
        <copy lang="zh_CN">罗氏近年在免疫治疗方面落后于抗癌对手默克，一直在急切地等待数字信息收集上的趋势转向。它2018年在美国的两笔收购可能会结出硕果。一个是基因测序公司Foundation Medicine，它可以通过血液样本中的DNA来确诊癌症，而不必做肿瘤活检。另一家是Flatiron Health，专门研究癌症方面的医疗档案，生成真实患者数据来为临床试验数据提供补充。这两家公司都能带来罗氏所说的对癌症的洞见。就像它的诊断业务一样，这些业务不但帮助罗氏推进自己的药物研发，还可以把服务卖给竞争对手，让它们自成一门生意。它们目前尚未盈利，但施万表示，有朝一日“洞见”业务可能成为罗氏的第三大支柱，规模可能赶上甚至超过诊断和制药业务。</copy>
        <copy lang="zh_TW">羅氏近年在免疫治療方面落後於抗癌對手默克，一直在急切地等待數字信息收集上的趨勢轉向。它2018年在美國的兩筆收購可能會結出碩果。一個是基因測序公司Foundation Medicine，它可以通過血液樣本中的DNA來確診癌症，而不必做腫瘤活檢。另一家是Flatiron Health，專門研究癌症方面的醫療檔案，生成真實患者數據來為臨床試驗數據提供補充。這兩家公司都能帶來羅氏所說的對癌症的洞見。就像它的診斷業務一樣，這些業務不但幫助羅氏推進自己的藥物研發，還可以把服務賣給競爭對手，讓它們自成一門生意。它們目前尚未盈利，但施萬表示，有朝一日“洞見”業務可能成為羅氏的第三大支柱，規模可能趕上甚至超過診斷和製藥業務。</copy>
      </paragraph>
      <paragraph>
        <copy lang="en_GB">There are potential pitfalls. Biology is as messy and unpredictable as nature itself. Data analytics may not be as useful in biotech as in other industries. Roche will not have the field to itself. Silicon Valley tech giants are already muscling in. And Europe, where Roche is based, has long been squeamish about data-gathering and privacy. If that continues to apply to medicine, it will hobble the region’s health-care industry.</copy>
        <copy lang="zh_CN">这类业务也有隐患。生物学就和大自然本身一样混乱且不可预测。数据分析在生物技术领域可能不如在其他行业有用。罗氏将无法独占这一领域。硅谷的科技巨头已经在强势挤入。而罗氏总部所在的欧洲长期都对数据收集和隐私问题神经敏感。如果这延及医药业，将阻碍欧洲医药业的发展。</copy>
        <copy lang="zh_TW">這類業務也有隱患。生物學就和大自然本身一樣混亂且不可預測。數據分析在生物技術領域可能不如在其他行業有用。羅氏將無法獨佔這一領域。硅谷的科技巨頭已經在強勢擠入。而羅氏總部所在的歐洲長期都對數據收集和隱私問題神經敏感。如果這延及醫藥業，將阻礙歐洲醫藥業的發展。</copy>
      </paragraph>
      <paragraph>
        <copy lang="en_GB">That said, Roche has a record of pulling off the unexpected. Stefan Schneider of Vontobel, a Swiss investment firm, notes that it has accomplished the rare feat of keeping profits ticking over even as patents on its three biggest cancer drugs, which had peak annual revenues of $21bn, have expired. Its immunotherapy drug, Tecentriq, has recently shown promising results in early-stage lung-cancer care, which may be a big breakthrough. And it has mastered the art of buying trendy biotech firms without spoiling their innovative fizz.</copy>
        <copy lang="zh_CN">不过，罗氏素有做成意想不到的事的本领。瑞士投资公司Vontobel的斯特凡·施耐德（Stefan Schneider）指出，在它的三大抗癌药物的专利过期之后（年收入峰值曾高达210亿美元），它仍然保持了盈利，这是一个罕见的壮举。罗氏的免疫治疗药物特善奇（Tecentriq）近期在早期肺癌治疗方面显现出了令人振奋的效果，有可能是一项重大突破。它还掌控了收购新兴生物技术公司却不破坏其创新活力的要诀。</copy>
        <copy lang="zh_TW">不過，羅氏素有做成意想不到的事的本領。瑞士投資公司Vontobel的斯特凡·施耐德（Stefan Schneider）指出，在它的三大抗癌藥物的專利過期之後（年收入峰值曾高達210億美元），它仍然保持了盈利，這是一個罕見的壯舉。羅氏的免疫治療藥物特善奇（Tecentriq）近期在早期肺癌治療方面顯現出了令人振奮的效果，有可能是一項重大突破。它還掌控了收購新興生物技術公司卻不破壞其創新活力的要訣。</copy>
      </paragraph>
      <subtitle>
        <copy lang="en_GB">Black Schwan</copy>
        <copy lang="zh_CN">黑天鹅施万</copy>
        <copy lang="zh_TW">黑天鵝施萬</copy>
      </subtitle>
      <paragraph>
        <copy lang="en_GB">Indeed, its success vindicates long-term thinking and shows that shareholders’ focus on notions like sustainability can co-exist with commercial success. For all the Hoffmann family’s influence, Mr Schwan is no softy. He defends high drug prices in America. He believes in strong intellectual-property protection. When America’s government this year threw its support behind patent waivers for covid-19 vaccines, he compared it to communist East Germany’s nationalisation of drugmakers. Roche may be unusual. As one of Europe’s few world-class megafirms, it is ballsy, too. ■</copy>
        <copy lang="zh_CN">的确，罗氏的成功证明了长线思维的正确性，也显示出股东关注可持续发展这类概念不必然与商业成功冲突。而尽管霍夫曼家族拥有强大影响力，施万也非弱咖。他为美国的高药价辩护。他相信强有力的知识产权保护。当美国政府今年提出支持豁免新冠疫苗的专利时，他把这比作共产主义东德对制药企业的国有化。罗氏或许与众不同。作为欧洲为数不多的世界级巨头公司之一，它也胆魄过人。</copy>
        <copy lang="zh_TW">的確，羅氏的成功證明了長線思維的正確性，也顯示出股東關注可持續發展這類概念不必然與商業成功衝突。而儘管霍夫曼家族擁有強大影響力，施萬也非弱咖。他為美國的高葯價辯護。他相信強有力的知識產權保護。當美國政府今年提出支持豁免新冠疫苗的專利時，他把這比作共產主義東德對製藥企業的國有化。羅氏或許與眾不同。作為歐洲為數不多的世界級巨頭公司之一，它也膽魄過人。</copy>
      </paragraph>
    </content>
    <idioms/>
  </body>
</article>
